Syneron Medical Ltd. (ELOS)
Loading...
Symbols:
ELOS Forum Topics
- All Comments on ELOS
- General Discussion on ELOS
- Syneron Medical's Superb Q2 Treatment [view article]
- Interview with Abba Horwitz, Old School Partners [view article]
- Screaming Value at Syneron Medical [view article]
- Baupost Group - Portfolio Holdings [view article]
- Seth Klarman of Baupost Group: Top 10 Holdings [view article]
- Get Back in the Truck and Buy Syneron [view article]
- Eight Women's Stocks [view article]
- Aesthetic Lasers Industry: CEOs Shed Some Light [view article]
- Syneron's Fountain of Youth: An Attractive Buying Opportunity [view article]
- Growth Stock Syneron Looks Attractive [view article]
- Jim Cramer's Mad Money Lightning Round Picks, 6/22/07 [view article]
loading ...Recent ELOS Articles
- Syneron Medical's Superb Q2 Treatment
- Interview with Abba Horwitz, Old School Partners
- Screaming Value at Syneron Medical
- Baupost Group - Portfolio Holdings
- Eight Women's Stocks
- Baupost Group - Portfolio Holdings
- Aesthetic Lasers Industry: CEOs Shed Some Light
- Baupost Group - Portfolio Holdings
- Syneron's Fountain of Youth: An Attractive Buying Opportunity
- Syneron Warns, Falls Hard - But Still Is Attractive
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Syneron Medical's Superb Q2 Treatment [view article]
CYNO qtly rev growth 30.10% vs ELOS 1.90%. CYNO ROA 10.35% vs ELOS 6.58%. CYNO ROE 16.4% vs ELOS 13.4%. Don't get me wrong, I own both and both are leaders in the industry, but CYNO is clearly outperforming CUTR, CLZR, ELOS, PMTI etc. ELOS hdqt in Israel is a definite risk and their share price is going to stay depressed until there's more stability in the Mid-East no matter how much they sell overseas. ELOS deferred LT liabilities far outweight CYNO minimal debt, not that it changes anything. ReplySyneron Medical's Superb Q2 Treatment [view article]
how is CYNO the market leader? ELOS pretty much beats CYNO in almost every category.FYI - CYNO does have debt, but that doesn't change anything. Reply
Syneron Medical's Superb Q2 Treatment [view article]
HELLOOOOOOO...... CUTR? CLZR? How in the world can you talk about no debt successfull companies in this market without even mentioning the market leader? CYNOSURE Replyababy
Interview with Abba Horwitz, Old School Partners [view article]
Syneron (ELOS) outshined it's peers??????????? Better take a look at the clear industry leader Cynosure (CYNO) ReplyScreaming Value at Syneron Medical [view article]
rearward looking analysis. without being exact, 14% growth in a part of the business (int'l) that is almost half of the business, and 5% in the total business, means the u.s. business was flat to down last quarter. of course, int'l sales were boosted by currency, so total company constant currency sales were likely up very little if at all.with $4 gas, a million homes in foreclosure, etc sales in the u.s. should be headed down. you cannot look backward with a situation like this. based on q1 free cash flow, stock is at 14x, not the numbers you cite. where do you think the free cash flow trends are headed, anyway? up? not likely.
plus they played games last quarter by reversing a tax item, eps would have been -0.05 less otherwise. dso's jumped 16. mea culpa coming in the next qtr or so. do you do any analysis at all??? Reply
ababy
Screaming Value at Syneron Medical [view article]
I notice you cite CYNO in your article. Better growth rate and prospects plus a US company. Unfortunate that ELOS is hdqt. in Israel. Major factor in their discounted stock price, and unlikely it will change soon. Replysack
Screaming Value at Syneron Medical [view article]
I bought this one at $15.20 in April. At the time, it was trading at an EV/forward earnings multiple of about 5.7x. It still looks pretty cheap, if it can maintain earnings at this level. The company doesn't give earnings guidance, but it does guide for revenue. They expect a 10% increase in revenue this year. ReplyPursley
Seth Klarman of Baupost Group: Top 10 Holdings [view article]
Seth Klarman's speech at MIT is one of the most important speeches I've ever read. Replysack
Get Back in the Truck and Buy Syneron [view article]
Just picked up some at $15.20 this week. Looks less expensive here, particularly considering the cash horde. ReplyEditors
General Discussion on ELOS
Is this a buy or a sell? ReplyEight Women's Stocks [view article]
good list of stocks elos looks strogest ReplyAesthetic Lasers Industry: CEOs Shed Some Light [view article]
thanks. Didn't see that you could enlarge it. I'm not too smart sometimes. ReplyBrochstein
Aesthetic Lasers Industry: CEOs Shed Some Light [view article]
Click on it again (twice) and it should be clear - works for me... ReplyAesthetic Lasers Industry: CEOs Shed Some Light [view article]
Is anyone else having problems with the image attached? When I enlarge it, it seems to be very blurry. Is there a way to fix this? ReplySyneron's Fountain of Youth: An Attractive Buying Opportunity [view article]
See this article:seekingalpha.com/artic...
If CUTR is hurting, so is ELOS. P&G deal hasn't kicked in yet and when it does we still don't know what the new margins will be. There is still some downside potential ($14/$15 range) until Q4 results are in.
CrossProfit Reply